By Vitality Peps Research Team, updated August 2026.
BPC-157 and TB-500 are routinely mentioned in the same breath, which has produced a lot of confusion about what they actually are. They are unrelated molecules studied through different pathways. Here is the comparison, restricted to what the literature supports.
BPC-157 is a 15 amino acid synthetic peptide based on a sequence identified in gastric juice. TB-500 is a synthetic peptide corresponding to a short active region associated with thymosin beta-4, a protein present in most mammalian cell types.
Different length, different parent sequence, different research history. They are not variants of one another.
BPC-157 research focuses largely on angiogenic signalling and cytoprotective effects in preclinical tissue models.
TB-500 research focuses on actin binding and cell migration, which is a mechanistically distinct route to a superficially similar research question.
Both bodies of work are preclinical. Neither has an established controlled human clinical evidence base.
Combination use is widely discussed in informal communities and thinly represented in peer reviewed literature. There is no controlled evidence establishing an interaction profile between the two in humans. Any protocol that presents one as standard is not reflecting the published record.
Both compounds are supplied by Vitality Peps for in vitro laboratory research only. Not for human or veterinary consumption.
For research purposes only. Not for human consumption.